上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Alpelisib (Synonyms: BYL-719) 纯度: 99.88%
Alpelisib (BYL-719) 是有效,选择性的,具有口服活性的 PI3Kα 抑制剂。Alpelisib (BYL-719) 对 PIK3CA 突变癌具有靶向性。Alpelisib (BYL-719) 抑制 p110α、p110γ、p110δ、p110β 的 IC50 分别为 5 nM,250 nM,290 nM,1200 nM。具有抗肿瘤活性。
Alpelisib Chemical Structure
CAS No. : 1217486-61-7
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥825 | In-stock | |
5 mg | ¥750 | In-stock | |
10 mg | ¥1280 | In-stock | |
50 mg | ¥3600 | In-stock | |
100 mg | ¥5500 | In-stock | |
200 mg | ¥8800 | In-stock | |
500 mg | 询价 | ||
1 g | 询价 |
* Please select Quantity before adding items.
Alpelisib 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- FDA-Approved Drug Library Mini
- Bioactive Compound Library Plus
- Kinase Inhibitor Library
- PI3K/Akt/mTOR Compound Library
- Stem Cell Signaling Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- Autophagy Compound Library
- Anti-Aging Compound Library
- Drug Repurposing Compound Library
- Differentiation Inducing Compound Library
- Oxygen Sensing Compound Library
- Anti-COVID-19 Compound Library
- Glycolysis Compound Library
- Cytoskeleton Compound Library
- Orally Active Compound Library
- Chemical Probe Library
- FDA Approved & Pharmacopeial Drug Library
- Anti-Breast Cancer Compound Library
- Anti-Lung Cancer Compound Library
- Anti-Pancreatic Cancer Compound Library
- Anti-Blood Cancer Compound Library
- Targeted Therapy Drug Library
- Anti-Cancer Metabolism Compound Library
- Angiogenesis Related Compound Library
- Glucose Metabolism Compound Library
- Targeted Diversity Library
- Anti-Liver Cancer Compound Library
- Rare Diseases Drug Library
- Anti-Colorectal Cancer Compound Library
生物活性 |
Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity[1][2][3]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1][2] |
|
||||||||||||||||
体外研究 (In Vitro) |
Alpelisib (BYL-719) potently inhibits the 2 most common PIK3CA somatic mutations (H1047R, E545K; IC50s~4 nM). Alpelisib potently inhibits Akt phosphorylation in cells transformed with PI3Kα (IC50=74±15 nM) and shows significant reduced inhibitory activity in PI3Kβ or PI3Kδ isoforms transformed cells (≥15-fold compared with PI3Kα)[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay[3]
Cell Cycle Analysis[3]
|
||||||||||||||||
体内研究 (In Vivo) |
Alpelisib (BYL-719) (12.5 mg/kg and 50 mg/kg for C57Bl/6J mice; 50 mg/kg for female Rj:NMRI-nude mice; oral administration; daily) significantly reduces tumor volumes and deposition of ectopic bone matrix[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
441.47 |
||||||||||||||||
Formula |
C19H22F3N5O2S |
||||||||||||||||
CAS 号 |
1217486-61-7 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 83.33 mg/mL (188.76 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务